Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Tempest TherapeuticsTPST +1.58%32 3-Year EPS without NRI Growth Rate is 46.00% as of Mar. 2026, which is 11% above its 10-year median of 41.40. GuruFocus rates TPST with a GF Score™ of 32/100. The stock has 1 warning sign investors should review. Among 1,164 Biotechnology companies, Tempest Therapeutics ranks better than 82.3% on this metric.
During the past 3 years, the average EPS without NRI Growth Rate was 46.00% per year.
During the past 5 years, the average EPS without NRI Growth Rate was 33.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 6 years, the highest 3-Year average EPS without NRI Growth Rate of Tempest Therapeutics was 46.00% per year. The lowest was 12.90% per year. And the median was 41.40% per year.
Tempest Therapeutics (NAS:TPST) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Tempest Therapeutics 3-Year EPS without NRI Growth Rate Related Terms
TPST vs ICU, INTI, OSRH: 3-Year EPS without NRI Growth Rate Comparison
For the Biotechnology subindustry, Tempest Therapeutics's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tempest Therapeutics 3-Year EPS without NRI Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Tempest Therapeutics's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Tempest Therapeutics's 3-Year EPS without NRI Growth Rate falls into.
Tempest Therapeutics 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 46.00% mean?
Tempest Therapeutics (TPST) has a 3-Year EPS without NRI Growth Rate of 46.00% as of Mar. 2026. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Tempest Therapeutics and its competitors. This is 11% above median its historical median of 41.40. Over the past decade, Tempest Therapeutics' 3-Year EPS without NRI Growth Rate has ranged from 12.90 to 46.00. According to the industry distribution chart, Tempest Therapeutics ranks #206 out of 1164 companies in the Biotechnology industry, placing it in the top 17.7%.
Is Tempest Therapeutics' 3-Year EPS without NRI Growth Rate too high?
Tempest Therapeutics' current 3-Year EPS without NRI Growth Rate of 46.00% is 11% above median its 10-year median of 41.40. Over the past 10 years, this metric has ranged from a low of 12.90 to a high of 46.00. The Biotechnology industry median 3-Year EPS without NRI Growth Rate is 16.20. Tempest Therapeutics' value of 46.00% is 184% above this industry median. Based on the distribution chart, Tempest Therapeutics ranks #206 out of 1164 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Tempest Therapeutics has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Tempest Therapeutics' 3-Year EPS without NRI Growth Rate compare to ICU and INTI?
According to the Biotechnology industry distribution chart, Tempest Therapeutics ranks #206 out of 1164 companies for 3-Year EPS without NRI Growth Rate. This places Tempest Therapeutics in the top 18% of its industry — outperforming the majority of peers. The industry median 3-Year EPS without NRI Growth Rate is 16.20. Tempest Therapeutics' value of 46.00% is 184% above this benchmark. Historically, Tempest Therapeutics' own 3-Year EPS without NRI Growth Rate has ranged from 12.90 to 46.00 over the past decade. While the company's 10-year median is 41.40 vs. the industry median of 16.20, Tempest Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Biotechnology company?
The median 3-Year EPS without NRI Growth Rate among Biotechnology companies is 16.20, based on 1,164 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tempest Therapeutics's current 3-Year EPS without NRI Growth Rate of 46.00% is 184% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Tempest Therapeutics and its competitors. For the Biotechnology industry, the median 3-Year EPS without NRI Growth Rate is 16.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tempest Therapeutics's current 3-Year EPS without NRI Growth Rate is 46.00%, which is 11% above median its own 10-year median of 41.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tempest Therapeutics stock overvalued right now?
Tempest Therapeutics (TPST) has a current 3-Year EPS without NRI Growth Rate of 46.00%. The current 3-Year EPS without NRI Growth Rate is 46.00%, which is 11% above median its 10-year median of 41.40 and 184% above the Biotechnology industry median of 16.20. Tempest Therapeutics' overall GF Score™ is 32/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For Tempest Therapeutics (TPST), the current 3-Year EPS without NRI Growth Rate is 46.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets. Company's small-molecule product candidate, amezalpat (previously known as TPST-1120), has completed a Phase 2 study in first-line hepatocellular carcinoma and the second small-molecule product candidate is TPST-1495, plans to initiate a Phase 2 study for in familial adenomatous polyposis.
32GF Score
Get the complete analysis for TPST
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPST has been successfully added to your 
